Use of coumarether and composition thereof

A kind of technology of coumarin and compound, applied in the field of pharmacy

Inactive Publication Date: 2009-04-29
XIANGBEI WELMAN PHARMA CO LTD
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] However, there is no report on the new use of coumarin compounds in the treatment of leukopenia

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of coumarether and composition thereof
  • Use of coumarether and composition thereof
  • Use of coumarether and composition thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0070] The compound wedelolide extracted from Eclipta alba

[0071] (1) soaking and filtering

[0072] Eclipta whole grass 300kg, fully immersed in 0.75 tons of ethanol (concentration 95%)→soak overnight (10 hours)→coarse filtration, thereby removing the whole grass residue (retention)→net filtration (suction filtration) or high-speed centrifugation (10000rpm, 10 minutes), thereby removing dust and fine residue → green clarified filtrate.

[0073] (2) Ethanol recovery

[0074] Recover ethanol by distillation, the temperature does not exceed 60°C → distill for 2 hours each time, remove the extract in the reaction kettle to the collection bucket (the extract is dark dark green, slightly viscous) → repeat the above steps until all ethanol is recovered .

[0075] (3) Second soaking and back distillation

[0076] Recover 0.75 tons of ethanol, re-soak the whole herb residue → soak overnight, the requirements for coarse filtration, net filtration and distillation recovery are the...

Embodiment 2

[0089] Therapeutic effect of wedelolide on cyclophosphamide-induced leukopenia in mice

[0090] Experimental animals: 60 male SPF grade C57BL / 6 mice, purchased from Shanghai Slack Experimental Animal Co., Ltd., weighing 22-24 g. Raised in SPF grade animal room, 12h light / 12h dark, free intake of feed and water.

[0091] experimental method:

[0092] 1. Modeling method:

[0093] In addition to the normal control group, the rest of the animals were randomly divided into 5 groups, intraperitoneal injection of cyclophosphamide 100mg / kg for 3 consecutive days to create a leukopenia model;

[0094] 2. Administration situation:

[0095] (1) normal group, (2) model group, mice in (1) (2) group were given normal saline with a volume of 0.1ml / 10g; (3) (4) groups were Li Kejun high and low dose groups : Mice were given doses of 40mg / kg and 10mg / kg of Li Kejun respectively; (5) (6) (7) groups were APL-1 high, middle and low dose groups: mice were given doses of 100mg / kg kg, 25mg / kg, ...

Embodiment 3

[0107] Wedelide pair 60 Protective effect of Co-γ-induced bone marrow injury in mice

[0108] Experimental animals: 60 male SPF grade ICR mice, purchased from Shanghai Slack Experimental Animal Co., Ltd., weighing 22-24 g. Raised in SPF grade animal room, 12h light / 12h dark, free intake of feed and water.

[0109] experimental method:

[0110] 1. Modeling method:

[0111] Except for the animals in the normal control group, the rest of the animals were randomly divided into 5 groups. 60 Co-γ ray was irradiated once with a dose of 7.50Gy (dose rate 450 Rm / min).

[0112] 2. Administration situation:

[0113] (1) normal control group, (2) model group, (1) (2) group mice were given normal saline with a volume of 0.1ml / 10g; Groups: Mice were given 40 mg / kg and 10 mg / kg of Likejun; (5) (6) (7) groups were APL-1 high, medium and low dose groups: Mice were given 100 mg / kg, 25mg / kg, 5mg / kg of APL-1. All the above groups were intragastrically administered 7 days before irradiati...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention pertains to the pharmacology field and discloses the application of a Tonka-bean ether compound or a composition containing the compound in preventing or treating the relevant diseases caused by the reduction of leucocyte. Therefore, the Tonka-bean ether compound or the composition thereof can be used for treating the reduction of leucocyte caused by various reasons, particularly effectively improving the leucocyte reduction symptoms of patients after receiving radiotherapy and chemotherapy and effectively resisting immune suppression caused by chemotherapeutics, thereby improving the immune reaction of organism.

Description

technical field [0001] The invention belongs to the field of pharmacy, and more specifically, the invention relates to a new application of a coumarin compound or a composition containing the compound. Background technique [0002] The white blood cell count in human peripheral blood continued to be lower than the normal value (4×10 9 / L) is called leukopenia, the most common being neutropenia. Patients may be asymptomatic or have nonspecific symptoms such as fatigue, anorexia, decreased energy, and a predisposition to infection. Whether the patient has co-infection depends on the degree of neutropenia. The most common sites of infection are the lungs, urinary tract, and skin. Leukopenia can be divided into two types: hereditary and acquired, among which acquired is the majority. Drugs, radiation, infection, toxins, etc. can all reduce leukocytes, and drugs are the most common. During treatment, the cause of leukopenia should be carefully searched, and appropriate treat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/366A61P37/06
Inventor 俞强
Owner XIANGBEI WELMAN PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap